Logo

Log In Sign Up |  An official publication of: American College of Emergency Physicians
Navigation
  • Home
  • Multimedia
    • Podcasts
    • Videos
  • Clinical
    • Airway Managment
    • Case Reports
    • Critical Care
    • Guidelines
    • Imaging & Ultrasound
    • Pain & Palliative Care
    • Pediatrics
    • Resuscitation
    • Trauma & Injury
  • Resource Centers
    • mTBI Resource Center
  • Career
    • Practice Management
      • Benchmarking
      • Reimbursement & Coding
      • Care Team
      • Legal
      • Operations
      • Quality & Safety
    • Awards
    • Certification
    • Compensation
    • Early Career
    • Education
    • Leadership
    • Profiles
    • Retirement
    • Work-Life Balance
  • Columns
    • ACEP4U
    • Airway
    • Benchmarking
    • Brief19
    • By the Numbers
    • Coding Wizard
    • EM Cases
    • End of the Rainbow
    • Equity Equation
    • FACEPs in the Crowd
    • Forensic Facts
    • From the College
    • Images in EM
    • Kids Korner
    • Medicolegal Mind
    • Opinion
      • Break Room
      • New Spin
      • Pro-Con
    • Pearls From EM Literature
    • Policy Rx
    • Practice Changers
    • Problem Solvers
    • Residency Spotlight
    • Resident Voice
    • Skeptics’ Guide to Emergency Medicine
    • Sound Advice
    • Special OPs
    • Toxicology Q&A
    • WorldTravelERs
  • Resources
    • ACEP.org
    • ACEP Knowledge Quiz
    • Issue Archives
    • CME Now
    • Annual Scientific Assembly
      • ACEP14
      • ACEP15
      • ACEP16
      • ACEP17
      • ACEP18
      • ACEP19
    • Annals of Emergency Medicine
    • JACEP Open
    • Emergency Medicine Foundation
  • About
    • Our Mission
    • Medical Editor in Chief
    • Editorial Advisory Board
    • Awards
    • Authors
    • Article Submission
    • Contact Us
    • Advertise
    • Subscribe
    • Privacy Policy
    • Copyright Information

Does Cellulitis Treatment Need to Cover MRSA Infection?

By David A. Talan, MD | on August 15, 2017 | 1 Comment
Features
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
Print-Friendly Version

Dr. Greg Moran (left) and Dr. David Talan.The questions I get asked most are, “How do you treat cellulitis? Do I need to cover methicillin-resistant Staphylococcus aureus (MRSA)?”

You Might Also Like
  • Staphylococcus Aureus Susceptibility Changing in Pediatric Population
  • Pearls from Emergency Medicine Literature on Skin Conditions, Sepsis, Chest Pain, and More
  • Antibiotic Therapy for Abscesses Medical Dogma Challenged by Evidence-Based Research, Outcomes
Explore This Issue
ACEP Now: Vol 36 – No 08 – August 2017

With the emergence of community-associated MRSA as the most common cause of purulent skin infections in the United States, treatment of cellulitis (without a wound or discharge) has veered toward combination cephalexin and trimethoprim/sulfamethoxazole (TMP/SMX), the latter antibiotic added to cover MRSA. Recently, my colleagues and I published the results of a placebo-controlled trial that demonstrated that TMP/SMX treatment of patients with a drained skin abscess (most caused by MRSA) was associated with better outcomes (eg, higher cure rates and lower rates of recurrences, additional drainage procedures, hospitalizations, and household infections). So it’s logical that MRSA coverage would lead to better outcomes for cellulitis.

Infectious Diseases Society of America (IDSA) treatment guidelines state that uncomplicated cellulitis can be treated with just penicillin, providing fodder for yet another target for ED antibiotic-overuse shaming. Get real; in practice, no one, not even an infectious disease specialist, uses penicillin alone to treat cellulitis, except maybe for redness around the rim of a syphilitic chancre!

Unlike with abscesses, we almost never know the cause of cellulitis because there’s nothing to culture. Studies have tried unsuccessfully to use conventional cultures of skin biopsies. You may recall being directed as an intern to aspirate the leading edge. All for naught. Serological studies have suggested -strep, but these tests might yield false positives. Rarely, a blood culture kicks out a strep or staph, but these cases hardly reflect usual circumstances. Our group even tried to unlock this mystery by comparing polymerase chain reaction and pyrosequencing results from skin biopsies of the infected and opposite limb uninfected site with no luck.1

In the May 23, 2017, issue of JAMA, our five-ED research group reported on the first large trial to directly address whether the addition of an antibiotic with MRSA activity resulted in better outcomes among patients followed for four to six weeks. Five-hundred mostly adult patients with cellulitis were randomized to receive either oral cephalexin (500 mg QID) plus placebo or cephalexin (500 mg QID) plus TMP/SMX (2 DS BID) for seven days. This was “pure” cellulitis without a wound or drainage.

As you can see from Table 1, outcomes were similar between the groups in terms of initial cure rates, recurrent infections, and additional drainage procedures. Of interest was that among the minority who failed in each group, some developed abscesses or wounds that grew MRSA. This suggested that MRSA plays a role in some cellulitis cases, but overall, adding an antibiotic with MRSA activity did not improve outcomes.

Table 1: Effectiveness of Adding a MRSA-Targeting Antibiotic to Cellulitis Treatment

Table 1: Effectiveness of Adding a MRSA-Targeting Antibiotic to Cellulitis Treatment

I am next most frequently asked, “Do you really work with Dr. Greg Moran?” Yes, so for this article, I interviewed Gregory J. Moran, MD, at the department of emergency medicine and division of infectious diseases at Olive View–UCLA Medical Center, David Geffen School of Medicine at UCLA in Los Angeles, who was the paper’s first author.

Pages: 1 2 3 | Single Page

Topics: AntibioticCellulitisEmergency DepartmentEmergency MedicineInfectious DiseaseMethicillin-resistant Staphylococcus aureusPatient Careskin diseaseTreatment

Related

  • EM Runs in the Family

    February 26, 2025 - 0 Comment
  • Settling the Cefepime versus Piperacillin-Tazobactam Debate

    November 7, 2024 - 0 Comment
  • Updates in the Management of Severe Sepsis and Septic Shock

    June 12, 2024 - 1 Comment

Current Issue

ACEP Now: July 2025

Download PDF

Read More

One Response to “Does Cellulitis Treatment Need to Cover MRSA Infection?”

  1. December 11, 2019

    Cellulitis Specialist Reply

    Great Post about cellulitis treatment. Thanks for sharing.

Leave a Reply Cancel Reply

Your email address will not be published. Required fields are marked *


*
*

Wiley
  • Home
  • About Us
  • Contact Us
  • Privacy
  • Terms of Use
  • Advertise
  • Cookie Preferences
Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 2333-2603